The product will be used to make Xancor for preclinical, clinical, and commercial use as a treatment for cardiovascular inflammatory disease
BASF will exclusively manufacture a specialized form of astaxanthin, a key intermediate used to make Cardax Pharmaceuticals’ lead compound, Xancor™, for cardiovascular inflammatory disease.
BASF will produce this material in sufficient quantity for preclinical, clinical, and eventually commercial use, according to the joint development and supply agreement between the two companies.
As part of the agreement, Cardax has granted BASF an option for a royalty-bearing license for nutraceutical use of the specialized form of astaxanthin. All pharmaceutical applications of Xancor will remain the property of Cardax.